CSP EXAM TEST (SPECIALTY PHARMACY) 400 ACTUAL
QUESTIONS AND VERIFIED ANSWERS WITH RATIONALE
ALREADY A+ GRADE
This comprehensive question bank contains 400 multiple-choice questions
covering the Certified Specialty Pharmacist (CSP) exam curriculum. It
systematically addresses all core domains including clinical pharmacology,
specialty medication management, patient access and financial assistance, cold
chain logistics, REMS programs, drug interactions, adherence monitoring,
and regulatory compliance. Key topics include biologics, oral oncolytics,
immunotherapy agents, hepatitis C treatments, HIV therapies, multiple
sclerosis disease-modifying therapies, and inflammatory conditions. Each
question includes the correct answer and a detailed rationale explaining the
clinical reasoning and practice standards. The progression from foundational
concepts to complex clinical scenarios supports effective exam preparation for
specialty pharmacy certification and practice.
1. Which component of the specialty pharmacy model is primarily responsible for
coordinating manufacturer-provided patient assistance and prior-authorization
services?
A) Hub services
B) Cold chain management
C) USP <800> compliance
D) Inventory optimization
Answer: A
Rationale: Hub services act as a centralized liaison between manufacturers,
payers, and patients to manage patient assistance programs, benefits investigations,
and prior authorizations.
2. What is the most critical temperature range for storing a frozen biologic such as
pembrolizumab?
A) 2-8 degrees Celsius
, B) -20 degrees Celsius to -10 degrees Celsius
C) -80 degrees Celsius to -60 degrees Celsius
D) Room temperature
Answer: C
Rationale: Frozen biologics, including many oncology agents, require ultra-low
temperatures typically between -80 degrees Celsius and -60 degrees Celsius to
maintain product stability and integrity.
3. When a temperature excursion above the allowable range occurs during
transport, what is the first action a specialty pharmacist should take?
A) Discard the product immediately
B) Document the excursion and notify the manufacturer
C) Return the product to the pharmacy without investigation
D) Re-freeze the product on site
Answer: B
Rationale: Proper documentation of the excursion and immediate notification of
the manufacturer are essential first steps. The manufacturer's stability data will
determine whether the product can be salvaged or must be discarded.
4. USP Chapter <797> standards apply to which of the following activities?
A) Non-sterile compounding of oral powders
B) Sterile compounding of intravenous admixtures
C) Hazardous drug spill cleanup only
D) Cold chain temperature monitoring
Answer: B
Rationale: USP Chapter <797> establishes standards for sterile compounding to
prevent contamination and ensure the quality of sterile preparations, such as
intravenous admixtures.
5. Which of the following is a required element of URAC accreditation for
specialty pharmacies?
A) Mandatory use of robotic dispensing
B) Documented patient education program
C) Unlimited refill cycles for all drugs
D) Direct-to-patient shipping without consent
Answer: B
Rationale: URAC accreditation standards for specialty pharmacies require a
structured, documented patient education and counseling program to ensure
patients understand their therapy.
,6. Prior to initiating methotrexate therapy, a pharmacist should verify that the
patient has:
A) Normal baseline liver function tests and renal function
B) A recent colonoscopy within 6 months
C) An active hepatitis C infection
D) A documented allergy to sulfa drugs
Answer: A
Rationale: Methotrexate can cause hepatotoxicity and is renally excreted.
Baseline liver function tests and renal function assessment are critical to ensure
safe dosing and monitoring.
7. Which biologic agent is most commonly used as first-line therapy for moderate
to severe Crohn's disease?
A) Infliximab
B) Adalimumab
C) Prednisone
D) Vedolizumab
Answer: A
Rationale: Infliximab, a TNF-alpha inhibitor, is frequently used as a first-line
biologic agent for moderate to severe Crohn's disease.
8. Direct-acting antivirals (DAAs) for hepatitis C genotype 1a that are
contraindicated with strong CYP3A4 inducers include:
A) Sofosbuvir/velpatasvir
B) Glecaprevir/pibrentasvir
C) Simeprevir
D) Ribavirin
Answer: B
Rationale: Glecaprevir/pibrentasvir is metabolized by CYP3A4. Strong inducers
of this enzyme can significantly reduce its concentrations and lead to treatment
failure.
9. A key drug-interaction concern when prescribing ritonavir-boosted protease
inhibitors for HIV is:
A) Induction of CYP2D6 leading to decreased drug levels
B) Inhibition of CYP3A4 causing increased levels of concomitant medications
C) Activation of P-glycoprotein causing rapid clearance
D) No significant interactions exist
Answer: B
, Rationale: Ritonavir is a potent inhibitor of the CYP3A4 enzyme. When used as
a pharmacokinetic booster, it can significantly increase the blood levels of other
medications metabolized by this pathway, leading to toxicity.
10. Therapeutic drug monitoring (TDM) is most essential for which transplant
immunosuppressant?
A) Mycophenolate mofetil
B) Tacrolimus
C) Sirolimus
D) Prednisone
Answer: B
Rationale: Tacrolimus has a narrow therapeutic index and high inter-patient
variability in pharmacokinetics. Routine TDM is essential to maintain levels in the
therapeutic range and prevent rejection or toxicity.
11. The primary safety concern associated with natalizumab therapy for multiple
sclerosis is:
A) Hepatotoxicity
B) Progressive multifocal leukoencephalopathy (PML)
C) Renal failure
D) Hyperglycemia
Answer: B
Rationale: Natalizumab is associated with an increased risk of progressive
multifocal leukoencephalopathy, a rare but severe opportunistic infection of the
central nervous system.
12. A REMS program for a disease-modifying therapy in MS typically requires:
A) Monthly laboratory monitoring for liver enzymes only
B) Patient enrollment, prescriber certification, and periodic safety assessments
C) No special monitoring beyond routine visits
D) Automatic refill authorization without pharmacy verification
Answer: B
Rationale: REMS programs for high-risk medications, such as some MS
therapies, often require patient enrollment, prescriber certification, and ongoing
safety monitoring to ensure safe use.
13. The preferred method for educating patients on subcutaneous self-injection of a
biologic using a pen device is:
A) Providing only a written pamphlet
QUESTIONS AND VERIFIED ANSWERS WITH RATIONALE
ALREADY A+ GRADE
This comprehensive question bank contains 400 multiple-choice questions
covering the Certified Specialty Pharmacist (CSP) exam curriculum. It
systematically addresses all core domains including clinical pharmacology,
specialty medication management, patient access and financial assistance, cold
chain logistics, REMS programs, drug interactions, adherence monitoring,
and regulatory compliance. Key topics include biologics, oral oncolytics,
immunotherapy agents, hepatitis C treatments, HIV therapies, multiple
sclerosis disease-modifying therapies, and inflammatory conditions. Each
question includes the correct answer and a detailed rationale explaining the
clinical reasoning and practice standards. The progression from foundational
concepts to complex clinical scenarios supports effective exam preparation for
specialty pharmacy certification and practice.
1. Which component of the specialty pharmacy model is primarily responsible for
coordinating manufacturer-provided patient assistance and prior-authorization
services?
A) Hub services
B) Cold chain management
C) USP <800> compliance
D) Inventory optimization
Answer: A
Rationale: Hub services act as a centralized liaison between manufacturers,
payers, and patients to manage patient assistance programs, benefits investigations,
and prior authorizations.
2. What is the most critical temperature range for storing a frozen biologic such as
pembrolizumab?
A) 2-8 degrees Celsius
, B) -20 degrees Celsius to -10 degrees Celsius
C) -80 degrees Celsius to -60 degrees Celsius
D) Room temperature
Answer: C
Rationale: Frozen biologics, including many oncology agents, require ultra-low
temperatures typically between -80 degrees Celsius and -60 degrees Celsius to
maintain product stability and integrity.
3. When a temperature excursion above the allowable range occurs during
transport, what is the first action a specialty pharmacist should take?
A) Discard the product immediately
B) Document the excursion and notify the manufacturer
C) Return the product to the pharmacy without investigation
D) Re-freeze the product on site
Answer: B
Rationale: Proper documentation of the excursion and immediate notification of
the manufacturer are essential first steps. The manufacturer's stability data will
determine whether the product can be salvaged or must be discarded.
4. USP Chapter <797> standards apply to which of the following activities?
A) Non-sterile compounding of oral powders
B) Sterile compounding of intravenous admixtures
C) Hazardous drug spill cleanup only
D) Cold chain temperature monitoring
Answer: B
Rationale: USP Chapter <797> establishes standards for sterile compounding to
prevent contamination and ensure the quality of sterile preparations, such as
intravenous admixtures.
5. Which of the following is a required element of URAC accreditation for
specialty pharmacies?
A) Mandatory use of robotic dispensing
B) Documented patient education program
C) Unlimited refill cycles for all drugs
D) Direct-to-patient shipping without consent
Answer: B
Rationale: URAC accreditation standards for specialty pharmacies require a
structured, documented patient education and counseling program to ensure
patients understand their therapy.
,6. Prior to initiating methotrexate therapy, a pharmacist should verify that the
patient has:
A) Normal baseline liver function tests and renal function
B) A recent colonoscopy within 6 months
C) An active hepatitis C infection
D) A documented allergy to sulfa drugs
Answer: A
Rationale: Methotrexate can cause hepatotoxicity and is renally excreted.
Baseline liver function tests and renal function assessment are critical to ensure
safe dosing and monitoring.
7. Which biologic agent is most commonly used as first-line therapy for moderate
to severe Crohn's disease?
A) Infliximab
B) Adalimumab
C) Prednisone
D) Vedolizumab
Answer: A
Rationale: Infliximab, a TNF-alpha inhibitor, is frequently used as a first-line
biologic agent for moderate to severe Crohn's disease.
8. Direct-acting antivirals (DAAs) for hepatitis C genotype 1a that are
contraindicated with strong CYP3A4 inducers include:
A) Sofosbuvir/velpatasvir
B) Glecaprevir/pibrentasvir
C) Simeprevir
D) Ribavirin
Answer: B
Rationale: Glecaprevir/pibrentasvir is metabolized by CYP3A4. Strong inducers
of this enzyme can significantly reduce its concentrations and lead to treatment
failure.
9. A key drug-interaction concern when prescribing ritonavir-boosted protease
inhibitors for HIV is:
A) Induction of CYP2D6 leading to decreased drug levels
B) Inhibition of CYP3A4 causing increased levels of concomitant medications
C) Activation of P-glycoprotein causing rapid clearance
D) No significant interactions exist
Answer: B
, Rationale: Ritonavir is a potent inhibitor of the CYP3A4 enzyme. When used as
a pharmacokinetic booster, it can significantly increase the blood levels of other
medications metabolized by this pathway, leading to toxicity.
10. Therapeutic drug monitoring (TDM) is most essential for which transplant
immunosuppressant?
A) Mycophenolate mofetil
B) Tacrolimus
C) Sirolimus
D) Prednisone
Answer: B
Rationale: Tacrolimus has a narrow therapeutic index and high inter-patient
variability in pharmacokinetics. Routine TDM is essential to maintain levels in the
therapeutic range and prevent rejection or toxicity.
11. The primary safety concern associated with natalizumab therapy for multiple
sclerosis is:
A) Hepatotoxicity
B) Progressive multifocal leukoencephalopathy (PML)
C) Renal failure
D) Hyperglycemia
Answer: B
Rationale: Natalizumab is associated with an increased risk of progressive
multifocal leukoencephalopathy, a rare but severe opportunistic infection of the
central nervous system.
12. A REMS program for a disease-modifying therapy in MS typically requires:
A) Monthly laboratory monitoring for liver enzymes only
B) Patient enrollment, prescriber certification, and periodic safety assessments
C) No special monitoring beyond routine visits
D) Automatic refill authorization without pharmacy verification
Answer: B
Rationale: REMS programs for high-risk medications, such as some MS
therapies, often require patient enrollment, prescriber certification, and ongoing
safety monitoring to ensure safe use.
13. The preferred method for educating patients on subcutaneous self-injection of a
biologic using a pen device is:
A) Providing only a written pamphlet
